Celldex Therapeutics Announces Pricing of Upsized Public Offering, Expected to Raise $400.4 Million
Celldex Therapeutics, Inc.(Celldex), a biopharmaceutical company focused on developing targeted immunotherapies for the treatment of cancer and other diseases, made a significant announcement today regarding the pricing of an upsized underwritten public offering of its common stock.The company revealed that it has priced 8,520,000 shares of its common stock at a public offering price of $47.00 per share, with the potential for an additional 1,278,000 shares to be offered under a 30-day option granted to the underwriters.
This public offering is expected to provide Celldex with gross proceeds of approximately $400.4 million, excluding underwriting discounts, commissions, and other expenses related to the offering.The company plans for the offering to close on or around March 5, 2024, pending customary closing conditions.
Celldex Therapeutics has been at the forefront of developing innovative immunotherapies that target specific cancer cells, offering new hope for patients battling difficult-to-treat cancers.The proceeds from this public offering will likely be used to further advance the company’s research and development efforts, potentially leading to groundbreaking advancements in the field of oncology.
Investors and industry analysts have been closely following Celldex’s progress, as the company continues to demonstrate its commitment to advancing novel therapies that have the potential to improve patient outcomes and change the landscape of cancer treatment.With the successful pricing of this public offering, Celldex is poised to accelerate its research and development initiatives, further solidifying its position as a leader in the biopharmaceutical industry.
In conclusion, Celldex Therapeutics’ upsized public offering represents a significant milestone for the company, signaling investor confidence in its innovative approach to developing targeted immunotherapies.As Celldex continues to make strides in the fight against cancer, the proceeds from this offering will play a crucial role in driving the advancement of potentially life-saving treatments.Investors, patients, and industry stakeholders alike will be eagerly anticipating the outcomes of Celldex’s research and development efforts, as the company works towards realizing its vision of transforming the standard of care for cancer patients.
Comments